MORFライブシグナル | Getagraph.comで利益を最大化

売る 107764 min ago

@ $37.26

発行日: 15 2月 2024 @ 05:46

リターン: -23.85%

前回のシグナル: 2月 15 - 04:06

前回のシグナル: 買う

リターン: 0.38 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:49):

Stats
本日の出来高	97 192.00
平均出来高	498 550
時価総額	1.42B
EPS	$0 ( 2024-04-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.88
ATR14	$0.0370 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rogers Bruce	Buy	7 400	Common Stock
2024-03-27	Rogers Bruce	Sell	7 400	Stock Option (right to buy Common Stock)
2024-03-18	Cooper Simon Peter	Buy	170 000	Employee Stock Options (right to buy)
2024-03-18	Cooper Simon Peter	Buy	14 000	Restricted Stock Unit
2024-03-18	Cooper Simon Peter	Buy	7 000	Restricted Stock Unit

INSIDER POWER
69.64
Last 99 transactions
Buy: 2 671 692 \| Sell: 511 174

ボリューム相関

長: -0.09 (neutral)

短: -0.32 (neutral)

Signal:(61.141) Neutral

Morphic Holding Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Morphic Holding Inc 相関 - 通貨/商品

-0.16
( neutral )

-0.18
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.02
( neutral )

-0.05
( neutral )

Morphic Holding Inc 財務諸表

Annual	2023
収益:	$521 000
総利益:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2023
収益:	$521 000
総利益:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2022
収益:	$70.81M
総利益:	$69.80M (98.58 %)
EPS:	$-1.550

FY	2021
収益:	$19.79M
総利益:	$19.79M (100.00 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.